Rankings
▼
Calendar
INMB Q1 2025 Earnings — INmune Bio, Inc. Revenue & Financial Results | Market Cap Arena
INMB
INmune Bio, Inc.
$35M
Q1 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$50,000
+257.1% YoY
Gross Profit
$50,000
100.0% margin
Operating Income
-$10M
-19810.0% margin
Net Income
-$10M
-19478.0% margin
EPS (Diluted)
$-0.43
QoQ Revenue Growth
+Infinity%
Cash Flow
Operating Cash Flow
-$7M
Free Cash Flow
-$7M
Stock-Based Comp.
$2M
Balance Sheet
Total Assets
$38M
Total Liabilities
$8M
Stockholders' Equity
$30M
Cash & Equivalents
$19M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$50,000
$14,000
+257.1%
Gross Profit
$50,000
$14,000
+257.1%
Operating Income
-$10M
-$11M
+10.1%
Net Income
-$10M
-$11M
+11.7%
← Q4 2024
All Quarters
Q2 2025 →